(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 11.13% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Grail's revenue in 2025 is $130,711,000.On average, 1 Wall Street analysts forecast GRAL's revenue for 2025 to be $5,375,771,023, with the lowest GRAL revenue forecast at $5,375,771,023, and the highest GRAL revenue forecast at $5,375,771,023. On average, 1 Wall Street analysts forecast GRAL's revenue for 2026 to be $5,865,694,038, with the lowest GRAL revenue forecast at $5,865,694,038, and the highest GRAL revenue forecast at $5,865,694,038.
In 2027, GRAL is forecast to generate $6,181,037,686 in revenue, with the lowest revenue forecast at $6,181,037,686 and the highest revenue forecast at $6,181,037,686.